Seminari d'Innovació (VHIR) "Presentation of successful cases in biomedical research entrepreneurship"

  Aula 114 del Mòdul Sud, Unitat Docent HUVH —
28/10/2019 -- From 10:00h to 11:00h
Organize :
Unitat d'Innovació, Vall d'Hebron Institut de Recerca (VHIR)
Modality: Presencial
Share it:

Dra. Judit Anido; Vall d'Hebron Institute of Oncology (VHIO) i Dr. Victor Franco Puntes; Principal Investigator of the group Cap CIBBIM-Nanomedicine. Pharmacokinetic Nanoparticles (VHIR)

"Presentation of successful cases in biomedical research entrepreneurship"

The VHIR’s Innovation Unit invites you to share the experience of these two outstanding sicentific entrepreneurs. Dr Anido has led the growth of Mosaic Biomedicals as CEO since its inception in 2012 until its merger with Northern in 2016, and as General Manager afterwards. Dr Puntes is ICREA Research Professor with joint appointments in VHIR and ICN2. He is co-founder of several spin offs, with special emphasis on “Applied Nanoparticles”.

Partipacion does’nt need previous registration, but the room has limited capacity

More information: Innovation -Vall d’Hebron Institute of Research (VHIR) -Tel: (+34) 93 489 40 11


Subscribe to our newsletters and be a part of Vall d'Hebron Campus

Select the newsletter you want to receive:

By accepting these conditions, you are agreeing to the processing of your personal data for the provision of the services requested through this portal, and, if necessary, for any procedures required by the administrations or public bodies involved in this processing, and their subsequent inclusion in the aforementioned automated file. You may exercise your rights to access, rectification, cancellation or opposition by writing to, clearly stating the subject as "Exercising of Data Protection Rights".
Operated by: Vall d’Hebron University Hospital Foundation – Research Institute.
Purpose: Manage the user’s contact information.
Legitimisation: Express acceptance of the privacy policy.
Rights: To access, rectify, and delete personal information data, as well to the portability thereof and to limit and/or oppose their use.
Source: The interested party themselves.